Finanzen von Lakewood-Amedex Biotherapeutics Inc (LABT)LABTLakewood-Amedex Biotherapeutics Inc

Evaluating the bottom line, Lakewood-Amedex Biotherapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -403.17%, provide a clear picture of how effectively LABT converts its operational activities into shareholder value.

In the context of the broader market, LABT competes directly with industry leaders such as CVKD and GOVX. With a market capitalization of $5.92M, it holds a significant position in the sector. When comparing efficiency, LABT's gross margin of N/A stands against CVKD's N/A and GOVX's N/A. Such benchmarking helps identify whether Lakewood-Amedex Biotherapeutics Inc is trading at a premium or discount relative to its financial performance.

The company has shown a significant turnaround in total equity, which increased to $4,331,083 in Q2 2026 from negative figures in previous quarters, indicating improved financial health.